CDRH Staff Credits Advocacy Groups For Patient Preference Guidance
This article was originally published in The Gray Sheet
Top CDRH officials say while they have been working to incorporate patient preference into their regulatory process, it was the push from patients to get more involved in the agency's decision making process that led the agency to develop a new draft guidance on the topic.
You may also be interested in...
US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.
FDA draft guidance lays out how to collect patient preference data and how to present the preferences on device labels. The guidance supports a growing emphasis by FDA to formally incorporate patient input into regulatory decision-making.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.